Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 5/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107206 | 0.80 | CTSK (0.37) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL13686137 | 0.80 | CA1 (0.36) | CTSKALDH1A1CA1CA2CA7 | |
| SCHEMBL13684411 | 0.79 | CA1 (0.39) | CTSKALDH1A1CA1CA2CA7 | |
| SCHEMBL14943744 | 0.78 | ALDH1A1 (0.34) | CTSKALDH1A1SMN1; SMN2 | |
| SCHEMBL15338731 | 0.77 | ALDH1A1 (0.33) | CTSKALDH1A1SMN1; SMN2 | |
| SCHEMBL12330393 | 0.75 | SMN1; SMN2 (0.37) | CTSKALDH1A1CTSSSMN1; SMN2 | |
| SCHEMBL12401065 | 0.74 | ALDH1A1 (0.32) | CTSKALDH1A1 | |
| SCHEMBL2434771 | 0.72 | TSHR (0.39) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL30170109 | 0.71 | CA14 (0.36) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL14037618 | 0.71 | DGAT1 (0.37) | CTSKCA1CA2CA7CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295879-A1 | NK1 Antagonists | OPKO HEALTH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-8207170-B2 | Heterocyclic substituted piperazines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2012-06-26 | — | — | US | disclosed |
| US-8026364-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8017616-B2 | Heterocyclic substituted pyridine compounds with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110065651-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION (US) | 2011-03-17 | — | — | US | disclosed |
| US-7879838-B2 | Chemokine receptor antagonists used for the treatment of inflammatory diseases, autoimmune diseases, transplant rejection, infectious diseases, drug sensitivity, ophthalmic inflammation, type I diabetes, viral meningitis and tumors | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-7868006-B2 | Heterocyclic substituted piperazines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2011-01-11 | — | — | US | disclosed |
| US-7799789-B2 | Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2010-09-21 | — | — | US | disclosed |
| US-7781437-B2 | Substituted heterocyclic compounds with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2010-08-24 | — | — | US | disclosed |
| US-7776862-B2 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100190759-A1 | NK 1 ANTAGONISTS | OPKO HEALTH, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7763616-B2 | Piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-20100168124-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-7709641-B2 | Neurokinin-1, substance P (NK1); serotonin reuptake inhibitors; for treating emesis, depression, anxiety and cough | OPKO HEALTH, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7566718-B2 | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7498438-B2 | Fused ring NK1 antagonists | SCHERING CORPORATION (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080292589-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE OR PHENYL COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION | 2008-11-27 | — | — | US | disclosed |
| US-7417045-B2 | Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2008-08-26 | — | — | US | disclosed |
| US-20070082913-A1 | Substituted heterocyclic compounds with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082913-A1 | Substituted heterocyclic compounds with CXCR3 antagonist activity | CXCR3, CXCL10, CXCR1 | CTSK 3331/4885ALDH1A1 996/4885CA1 1575/4885 |
| US-20100190759-A1 | NK 1 ANTAGONISTS | BDKRB1, PROKR1, NPSR1 | CTSK 473/4885ALDH1A1 825/4885CA1 2101/4885 |
| US-20110065651-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, CCR5 | CTSK 3261/4885ALDH1A1 898/4885CA1 1907/4885 |
| US-20080292589-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE OR PHENYL COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, CCR1 | CTSK 2517/4885ALDH1A1 1940/4885CA1 1812/4885 |
| US-20120295879-A1 | NK1 Antagonists | NPSR1, GRPR, PROKR1 | CTSK 716/4885ALDH1A1 1238/4885CA1 1995/4885 |
| US-20100168124-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, CXCL10 | CTSK 3087/4885ALDH1A1 1122/4885CA1 2034/4885 |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | CXCR3, CCR1, CCR5 | CTSK 2734/4885ALDH1A1 648/4885CA1 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.